Jessica K. Altman, MD, associate professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern Medicine, discusses an early-phase study of gilteritinib in 

-mutation—positive patients with acute myeloid leukemia (AML).

This phase I/II study, which was recently published in 

, investigated gilteritinib in these relapsed/refractory patients with AML, Altman explains. Patients were not required to have 

 mutations, but researchers did enrich the patient cohort to have a larger number of patients with 

 mutations. The dose-escalation study had a primary endpoint of determining the maximum-tolerated dose, as well as assessing the safety, tolerability, associated toxicities, and anti-leukemic activity of the drug. The phase II component explored the efficacy of the agent.

Results showed that the maximum-tolerated dose was 300 mg once daily and common side effects seen were fatigue, diarrhea, elevation of liver function test, she adds.

Videos

Jessica K. Altman, MD, associate professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern Medicine, discusses an early-phase study of gilteritinib in FLT3-mutation–positive patients with acute myeloid leukemia (AML).

Jessica K. Altman, MD

Articles

Dr. Altman on Gilteritinib in Patients With Relapsed/Refractory AML